ArticleJCI insight2022
CD8+ T cell-derived IL-13 increases macrophage IL-10 to resolve neuropathic pain.
Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07109817 (Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer), which is not on this map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (DETOXp)
Who cites it
53 citing papers in PubMed, 90 citations in OpenAlex.
- T cell-dependent modulation of pain behaviors in a rat model of recurring paclitaxel-induced peripheral neuropathy.Brain, behavior, & immunity - health · 2026Article
- Review
- Immune Cell Composition and Protein Biomarkers Correlate With PRP Treatment Outcomes in Knee Osteoarthritis.Orthopaedic journal of sports medicine · 2026Article
- Article
- Immuno-Inflammatory Mechanisms in the Chronification of Pain.Pain and therapy · 2026Review
- Diosmetin as an Effective Treatment for Cisplatin-Induced Neuropathic Pain in Mice which does not Cause Hepatic or Renal Biomarker Alterations.Molecular neurobiology · 2026Article
- Targeting molecular pathways in neuropathic cancer pain: from mechanisms to novel therapeutics.iScience · 2026Review
- Cellular and molecular basis of neuropathic pain.RMD open · 2026Review
- Macrophage-derived extracellular vesicles promote T cell-dependent inflammatory pain resolution.bioRxiv : the preprint server for biology · 2026Article
- Chemotherapy-induced peripheral neuropathy in breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Trigeminal ganglion interferon-γ signaling drives orofacial neuropathic pain in rats.The journal of headache and pain · 2025Article
- A role for fibroblast and mural cell subsets in a nerve ligation model of neuropathic pain?Brain, behavior, and immunity · 2025Article
- Longitudinal MRI identifies associations between cognitive decline, inflammatory markers, and hippocampal subregion volumes in individuals with knee osteoarthritis.Communications medicine · 2025Article
- Dupilumab, a Novel Treatment for Peripheral Neuropathy: A Case Series.Dermatology and therapy · 2025Article
- Sex Differences in the Regulation of Interleukins in Chronic Pain: A Widely Recognized but Difficult-to-Tackle Factor.International journal of molecular sciences · 2025Review
- Clinical and Molecular Barriers to Understanding the Pathogenesis, Diagnosis, and Treatment of Complex Regional Pain Syndrome (CRPS).International journal of molecular sciences · 2025Article
- Mast cell-derived chymases are essential for the resolution of inflammatory pain in mice.Pain · 2025Article
- Emerging role of macrophages in neuropathic pain.Journal of orthopaedic translation · 2025Review
- Predicting Treatment Outcomes in Patients with Low Back Pain Using Gene Signature-Based Machine Learning Models.Pain and therapy · 2025Article
- Low-Dose IL-2 Attenuates Neuropathic Pain via Treg Expansion in Rats.Journal of pain research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Understanding the endogenous mechanisms regulating resolution of pain may identify novel targets for treatment of chronic pain. Resolution of chemotherapy-induced peripheral neuropathy (CIPN) after treatment completion depends on CD8+ T cells and on IL-10 produced by other cells. Using Rag2-/- mice lacking T and B cells and adoptive transfer of Il13-/- CD8+ T cells, we showed that CD8+ T cells producing IL-13 were required for resolution of CIPN. Intrathecal administration of anti-IL-13 delayed resolution of CIPN and reduced IL-10 production by dorsal root ganglion macrophages. Depleting local CD206+ macrophages also delayed resolution of CIPN. In vitro, TIM3+CD8+ T cells cultured with cisplatin, apoptotic cells, or phosphatidylserine liposomes produced IL-13, which induced IL-10 in macrophages. In vivo, resolution of CIPN was delayed by intrathecal administration of anti-TIM3. Resolution was also delayed in Rag2-/- mice reconstituted with Havcr2 (TIM3)-/- CD8+ T cells. Our data indicated that cell damage induced by cisplatin activated TIM3 on CD8+ T cells, leading to increased IL-13 production, which in turn induced macrophage IL-10 production and resolution of CIPN. Development of exogenous activators of the IL-13/IL-10 pain resolution pathway may provide a way to treat the underlying cause of chronic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.